Borneol has the effects of awakening the mind,clearing away heat and relieving pain.There are many varieties of Chinese patent medicines containing borneol,which are widely used in clinical practice,butthe unreasonable use of these drugs is prominent,such as the use on incorrect syndrome,the repeated medication,and the long-term use.At the same time,the improper use of borneol recorded in many ancient Chinese medicine books has a high safety risk,and modern toxicology experiments have also been reported,which make this kind of drugs be the focus of rational drug use in hospitals.This consensus is aim to regulate the rational use of Chinese patent medicines containing borneol.This consensus is in the form of "consensus report",which is formed by 28 pharmaceutical experts from three-level medical institutions in many places across the country through Delphi method.The relevant Questionnaire was carried out before the formation of the consensus.The literature statistical analysis and evidence-based evaluations of relevant issues were also carried out during the formation of the consensus,and the expert opinions were synthesized by using the recognition and recommendation scores.Finally,21 statements and explanatory texts were formed in two parts of "basic principles for rational use" and "key principles for pharmaceutical evaluation and drug use guidance" of Chinese patent medicines containing borneol.The purpose of this work is to provide reference opinions on rational use and pharmaceutical evaluation of Chinese patent medicines containing borneol for pharmacists,doctors and medical insurance administrators in medical institutions.

Oral calcium channel blocker (CCB) is the most common long-term medication for cardiovascular diseases. Consequently, it is essential to construct a scientific and standardized clinical comprehensive evaluation system, and then formulate Expert Consensus on Clinical Comprehensive Evaluation of Oral CCBs to assist decision-making for the government and clinicians. The Third Xiangya Hospital of Central South University has organized the formulation of this expert consensus based on the Guideline for Clinical Comprehensive Evaluation of Medicine and Technical Guidelines for Clinical Comprehensive Evaluation of Medicine of Cardiovascular Diseases with the participation of 16 representative medical institutions in Hunan. The expert consensus systematically evaluated oral CCBs, especially in the therapy of hypertension and coronary artery diseases, from 6 dimensions, including safety, effectiveness, economy, accessibility, suitability and innovation. This expert consensus can provide a decision-making basis for the clinical rational drug use and selection of drugs for medical institutions, and provide reference for the construction of comprehensive evaluation system of other drugs.

Topical non-steroidal anti-inflammatory drugs (NSAIDs) are one of the major drugs to manage musculoskeletal pain. However, there’s no evidence-based recommendation about the dosage and administration, drug-drug interactions, administration in special population or other pharmacology-related content. To tackle the inadequate applicability of current guidelines in clinical practices, the Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association will develop standard guidelines for the rational use of topical NSAIDs in musculoskeletal pain through multi-disciplinary collaboration. The guideline will be formulated and reported by strictly following the steps specified in the WHO Handbook for Guideline Development. The guideline project team will apply Delphi method to establishing the PICO (population, intervention, control, outcome) questions, conduct systematic search and collate evidences. Based on the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) evidence recommendation table, the recommendations will be formulated in accordance with such factors as balance of pros and cons suggested by best available evidences, evidence quality, patient preferences, values and cost-effectiveness, etc. The guideline should be perfected via internal discussion in the guideline development group and external review, so as to finally develop an evidence-based guideline. Moreover, the guideline will focus on the most important issues concerned by the clinical medical professionals and patients with musculoskeletal pain when using the topical NSAIDs. Therefore, it will be a highly instructive and high-quality guideline for clinical practice, ultimately promotes the rational application of topical NSAIDs in clinical settings.

伊伐布雷定临床与药学实践专家共识